Related by context. All words. (Click for frequent words.) 72 Metastatic Melanoma 71 IMC #B 71 Phase 2b Clinical Trial 71 IMA# 70 Pivotal Phase 69 Phase III Pivotal 69 PROSTVAC VF 69 Advanced Melanoma 68 Trial Evaluating 68 Pivotal Phase III 68 oral prodrug 68 II Clinical Trial 68 Combination REOLYSIN R 68 Randomized Phase II 68 MAGE A3 ASCI 68 PANVAC VF 68 Phase IIb Trial 67 Meets Primary Endpoint 67 Completes Patient Enrollment 67 Randomized Phase 67 recurrent glioblastoma multiforme 67 Malignant Melanoma 67 PEG SN# 67 Initiate Phase 67 ZACTIMA 67 Hormone Refractory Prostate Cancer 67 rALLy clinical trial 67 CYT# potent vascular disrupting 67 budesonide foam 67 initiated Phase Ib 66 telomerase therapeutic 66 Tesetaxel 66 Successfully Completes Phase 66 Dose Escalation 66 Intravenous CP 66 tramiprosate Alzhemed TM 66 Aflibercept 66 evaluating tivozanib 66 recurrent glioma 66 Phase #b/#a clinical 66 elacytarabine 66 Relapsed Multiple Myeloma 66 Adjuvant Treatment 66 phase IIb clinical 66 alvespimycin 66 forodesine 66 investigational monoclonal antibody 66 Neoadjuvant 66 Sipuleucel T 66 relapsed MM 66 Phase 2b Trial 66 Metastatic Colorectal Cancer 66 solid tumors ZYBRESTAT 66 LymphoStat B belimumab 66 refractory metastatic 66 stage IIIb IV 65 Cloretazine ® 65 tanespimycin 65 receptor tyrosine kinase inhibitor 65 Phase III Clinical Trial 65 pharmacogenomic translational research 65 VEGFR2 inhibitor 65 SPRYCEL ® 65 antibody MAb 65 Vicriviroc 65 Initiate Phase III 65 MKC# MT 65 Achieves Primary Endpoint 65 CR# vcMMAE 65 GOUT 65 Previously Treated 65 mapatumumab 65 5 fluorouracil leucovorin 65 MEND CABG II 65 Second Pivotal Phase 65 Study Evaluating 65 Phase 1b Clinical Trial 65 Cerebril TM 65 Patient Enrollment 65 relapsing remitting MS RRMS 65 Treatment Naive Patients 65 heavily pretreated 65 galiximab 65 RECORD1 65 Temsirolimus 65 PROSTVAC TM 65 recurrent metastatic ovarian cancer 65 Pooled Analysis 65 demonstrated antitumor activity 65 First Patient Enrolled 65 lintuzumab SGN 65 fosbretabulin 65 Newly Diagnosed Multiple Myeloma 65 Bayer HealthCare Onyx Pharmaceuticals 65 Romidepsin 65 BR.# 65 Anthracycline 65 Patients Treated With 65 HCV RESPOND 2 64 Chronic Myeloid Leukemia 64 Brentuximab Vedotin SGN 64 compound INCB# 64 PSMA ADC 64 metastatic hormone refractory 64 Elotuzumab 64 Initiated Phase 64 phase IIb III 64 Initiates Phase II 64 Aplidin R 64 HCV SPRINT 64 Sapacitabine 64 Fast Track Status 64 BRIM2 64 Phase 2a Clinical Trial 64 GVAX ® 64 Topline Results 64 huC# DM4 64 TKB# 64 metastatic colorectal 64 novel VDA molecule 64 oral picoplatin 64 dasatinib Sprycel ® 64 ganetespib 64 TransVax ™ 64 INSPIRE Trial Phase III 64 Dapagliflozin 64 Exherin TM 64 BZL# 64 Quinamed 64 assessing T DM1 64 Orphan Status 64 APEX PD 64 unresectable stage 64 HCV Protease Inhibitor 64 riociguat 64 oral ridaforolimus 64 ALN VSP Phase 64 Abiraterone Acetate 64 Demonstrates Potent 64 relapsed refractory multiple myeloma 64 MEK Inhibitor 64 evaluating mipomersen 64 Personalized Immunotherapy 64 ELACYT 64 Oral Fingolimod 64 Phase 1b clinical trials 64 Phase IIIb clinical 64 Demonstrates Sustained 64 Malignant Glioma 64 recurrent GBM 64 Initiates Phase 2b 64 Improves Survival 64 signal detection CTSD 64 novel topoisomerase 64 trastuzumab DM1 T DM1 64 Node Positive 64 Phase III Trial 63 virus HCV protease inhibitor 63 DCVax R 63 orally administered inhibitor 63 APPRAISE 63 Phase 1a clinical 63 Phase Ib II 63 Golimumab 63 Phase IIb Clinical Trial 63 Metastatic Prostate Cancer 63 Randomized Double blind 63 BCIRG 63 Antitumor Activity 63 Phase Ib IIa 63 Safinamide 63 ACTEMRA TM 63 Phase III Trials 63 CIMZIA TM certolizumab pegol 63 MGd 63 Bezielle 63 BRIM3 63 CRLX# 63 CTAP# Capsules 63 Humanized Anti 63 Refractory Angina 63 Initiates Phase 63 trastuzumab DM1 63 Degarelix 63 treatment naive genotype 63 Xanafide 63 STRIDE PD 63 oral rivaroxaban 63 Allovectin 7 63 resistant hormone refractory 63 IMPACT IMmunotherapy 63 metastatic castration resistant 63 YONDELIS 63 Virulizin ® 63 ASCO GI 63 TransVax 63 HGS ETR2 63 phase IIa clinical 63 Adjuvant Chemotherapy 63 Vaccine Protects Against 63 randomized Phase IIb 63 SinuNase TM 63 recombinant PSMA vaccine 63 Severe Sepsis 63 Pivotal Study 63 Tarceva TM 63 KRN# 63 IMC A# 63 OMP #R# 63 Solazed TM 63 Interferon Beta 63 Cardiotoxicity 63 undergoing elective percutaneous 63 Peginterferon 63 Glufosfamide 63 oral nucleoside analogue 63 M# rationally 63 Epratuzumab 63 sunitinib Sutent ® 63 Evoltra ® 63 IRX 2 63 metastatic castrate resistant 63 LUX Lung 63 Initiates Phase III 63 pertuzumab 63 FOLOTYN ® 63 Genasense ® 63 dose escalation phase 63 superficial bladder cancer 63 including eniluracil ADH 63 MGN# 63 Lenocta TM 63 cMET 63 Cutaneous T 63 multicenter Phase 63 evaluating Actimmune 63 Archexin 63 Pralatrexate 63 Renal Cell Carcinoma 63 systemic anaplastic large 63 Neuvenge 63 Phase III Clinical Trials 63 Phase Ib clinical trials 63 Completes Enrollment 63 Antibody Drug Conjugate 63 TNFerade TM 63 ThermoDox ® clinical 63 Commences Phase 63 drug pipeline TAFA# 63 Telatinib 63 Advanced Renal Cell 63 Treatment Shows Promise 63 Gastric Cancer 62 torezolid phosphate 62 AEG# 62 Acute Ischemic Stroke 62 phase III isavuconazole 62 Hepatotoxicity 62 Investigational Drug 62 Proellex TM 62 Aryplase 62 PEGylated Fab fragment 62 Prostate AdenoCarcinoma Treatment 62 erlotinib Tarceva ® 62 midstage clinical 62 Initiates Enrollment 62 HCD# [002] 62 GRNVAC1 62 evaluating picoplatin 62 Ozarelix 62 TNFerade ™ 62 Pivotal Phase II 62 Newly Diagnosed Patients 62 Aptivus ® 62 multicenter phase 62 Relapsing Multiple Sclerosis 62 adalimumab Humira 62 Pivotal Trial 62 agonistic human 62 Pivotal Clinical Trial 62 Initiates Clinical 62 Randomized Phase III 62 Troxatyl 62 comparing alemtuzumab 62 Vaccine Candidate 62 Hedgehog Pathway Inhibitor 62 ARRY # 62 Cholesterol Levels SPARCL 62 Hormone Receptor Positive 62 Tyrosine Kinase Inhibitor 62 novel tubulin binding 62 essential thrombocythemia ET 62 AVOREN 62 vidofludimus 62 neratinib 62 Tezampanel 62 recurrent malignant glioma 62 Prednisone Against Refractory 62 FOLFOX6 chemotherapy regimen 62 unique alkylating agent 62 Evaluation Program CTEP 62 OvaRex R 62 Dendreon Provenge 62 ongoing Phase 1b 62 G#DT 62 PI3K/Akt pathway inhibitor 62 XL# SAR# 62 phase Ib 62 Pazopanib 62 Advanced Prostate Cancer 62 Renal Cell Carcinoma RCC 62 Multicenter Phase 62 Study Showed 62 CHAMPION PCI 62 Dyloject TM 62 DermaVir Patch 62 First Patient Dosed 62 REVIVE Diabetes 62 dimebon latrepirdine 62 metastatic pancreatic 62 APTIVUS 62 Complicated Skin 62 interferon gamma 1b 62 Pemetrexed 62 TRO# 62 includes TOLAMBA TM 62 IMPDH inhibitor 62 CALGB # [002] 62 Multicenter Randomized 62 EOquin TM phase 62 mertansine 62 elotuzumab 62 Exelixis XL# 62 INCB# [001] 62 non nucleoside inhibitor 62 Demonstrates Positive 62 Fulvestrant 62 Talactoferrin 62 Initiate Clinical Trial 62 pharmacokinetic PK study 62 achieved CCyR 62 Panzem R 62 Universal Flu Vaccine 62 Omacetaxine 62 evaluating T DM1 62 Peginterferon alfa 2b 62 PRTX 62 ENABLE Phase 2 62 HCV NS5B polymerase 62 unresectable Stage III 62 cediranib 62 R Bortezomib 62 Fibrillex TM 62 Lovaxin C 62 PXD# 62 Lung Cancer Trial 62 metastatic GIST 62 AAG geldanamycin analog 62 Phase III ADT 62 Recurrent Glioblastoma 62 refractory CLL 62 Fx #A 62 CCR5 mAb 62 Dose Ranging 62 Empatic ™ 62 candidate CRLX# 62 XL# anticancer compounds 62 HER2 positive metastatic breast 62 prostate cancer HRPC 62 intravesical infusion therapy 62 gastro intestinal inflammation 62 Alocrest 62 Refractory Hodgkin Lymphoma 62 LibiGel Phase III 62 OvaRex ® MAb 62 ZOLINZA 62 JAK Inhibitor 62 Follicular Lymphoma 62 sapacitabine CYC# 62 pan HDAC inhibitor 62 Eculizumab 62 generation DACH Platinum 62 metastatic HRPC 62 Initiates Clinical Trial 62 FUSILEV enhances 62 TOCOSOL Paclitaxel 62 Velcade bortezomib 62 Vaccine Adjuvant 62 Hepatocellular Carcinoma HCC 62 Oral Calcitonin 62 TO AVOID PREGNANCY WHILE 62 sunitinib malate 62 sorafenib Nexavar 62 BRAF inhibitor 62 dextromethorphan quinidine 62 EFAPROXYN 62 Allovectin 7 R 62 Cloretazine 62 Phase 2a Trial 62 Therapeutic Vaccine 62 Patients Receiving 61 Colorectal Cancer Patients 61 Prolongs Survival 61 Glioblastoma Multiforme 61 keloid scarring 61 Demonstrates Significant 61 Panzem R NCD 61 Myeloma Patients 61 Naive Patients 61 Drug Shows Promise 61 Novel Antibiotic 61 Hsp# Inhibitor 61 Daclizumab 61 imatinib Gleevec ® 61 Infected Patients 61 trastuzumab Herceptin R 61 LUMINATE 61 delivers fluocinolone acetonide FA 61 cisplatin gemcitabine 61 Tanespimycin 61 RhuDex 61 Randomized Controlled 61 Cervical Dysplasia 61 randomized controlled Phase 61 monoclonal antibody IgG1 Mab 61 BRAF mutated 61 Rigel R# 61 refractory chronic lymphocytic 61 OPT CHF 61 acyclovir Lauriad R 61 CCR9 antagonist 61 Pertuzumab 61 registrational Phase 61 Telik logo TELINTRA 61 placebo controlled Phase 61 sorafenib tablets 61 Pharmacokinetic Study 61 Cethromycin 61 antiretroviral naïve 61 PROSTVAC ® 61 cilengitide 61 Aggressive Reduction 61 TLK# 61 Confirmatory Phase 61 PORxin TM platforms 61 Randomized Study 61 Triapine 61 Albuferon TM 61 cancer mCRC 61 Completes Dosing 61 Stage IIB 61 Preclinical Models 61 metastatic renal cell 61 PrevOnco 61 GVAX R 61 dependent kinase inhibitor 61 neoadjuvant treatment 61 systemic RNAi therapeutic 61 AVASTIN 61 randomized controlled multicenter 61 pralatrexate injection folate analogue 61 de novo kidney transplant 61 http:/www.vivus.com 61 bortezomib Velcade R 61 Factor VIIa 61 Phase 2b Study 61 blinded randomized placebo controlled 61 HuMax EGFr 61 rALLy 61 Begins Dosing 61 enzastaurin 61 Pegloticase 61 Philadelphia Chromosome Positive 61 phase IIb trial 61 Dose Ranging Study 61 Bortezomib 61 MyVax R 61 Aplidin 61 relapsed leukemia 61 initiated Phase 1b 61 LE DT 61 Pivotal Trials 61 estramustine 61 metaglidasen 61 mGluR5 NAM 61 Bicifadine 61 Intervention Effectiveness 61 Hepatitis C Antiviral 61 Relapsed Refractory 61 dasatinib Sprycel 61 Enzastaurin 61 oncolytic virus therapies 61 MOZOBIL 61 phase IIa 61 registrational trial 61 Talabostat 61 Commence Phase 61 kidney urologic 61 Fixed Dose 61 imetelstat GRN#L 61 IIa Clinical Trial 61 Immunotherapeutic 61 MKC# 61 CCX# 61 Unresectable 61 R#/MEM # 61 GVAX Immunotherapy 61 personalized cellular immunotherapy 61 Soft Tissue Sarcoma 61 PNP inhibitor 61 SPEAR Study 61 CALGB 61 Seliciclib 61 BENLYSTA TM 61 Randomized Double Blind 61 HER2 Positive Breast Cancer 61 Demonstrates Efficacy 61 Trastuzumab DM1 61 Tarvacin Anti Cancer 61 Lung Cancer Drug 61 oral JAK1 61 aflibercept VEGF Trap 61 APTIVUS R 61 Blinatumomab 61 Hepatocellular Carcinoma 61 PRN FDA Approves 61 Monotherapy 61 Cerebral Amyloid Angiopathy 61 orally inhaled migraine 61 forodesine hydrochloride 61 Tipranavir 61 number NCT# ClinicalTrials.gov 61 ALSYMPCA 61 liposomal formulation 61 Annamycin 61 HCV polymerase inhibitors 61 BioNumerik 61 CIMZIA TM 61 Myelodysplastic Syndromes 61 nilotinib Tasigna ® 61 Acute Exacerbations 61 JAK2 Inhibitor 61 Maribavir 61 MADIT II 61 IIa clinical 61 initiate multicenter 61 ONCONASE R 61 HDL Selective Delipidation 61 SUTENT ® 61 Triapine R 61 LAB CGRP 61 triggers apoptosis programmed 61 randomized Phase 2b 61 Phase Ib clinical 61 TELCYTA 61 Initiate Phase II 61 nonmetastatic 61 Lenocta 61 Advanced Solid Tumors 61 HQK 61 CHARM Added 61 indolent follicular non 61 CYC# 61 ENESTnd 61 Files IND 61 Phase IIIb 61 QNEXA ® 61 Improved Survival 61 targeted radiotherapeutic 61 radiation sensitizer 61 MADIT 61 IMPACT DCM 61 lenalidomide Revlimid R 61 CEL SCI Phase III 61 Presents Positive 61 Romiplostim 61 LEUKINE 61 epigenetic therapies 61 CYP#A# CYP#D# 61 next generation URAT1 61 taxane refractory 61 selective modulator 61 Virulizin R 61 canakinumab 61 paclitaxel Taxol R 61 alpha folate receptor 61 recurrent metastatic 61 CML CP 61 Uterine Cancer 60 Preclinical Study 60 CBLC# 60 Matrix Phase 2b 60 investigational humanized monoclonal antibody 60 CLARITY study 60 hormone refractory metastatic prostate 60 Rheumatoid Arthritis Patients 60 dose escalation clinical 60 hypoxia activated prodrug 60 RhuDex ® 60 Treatment Naïve 60 LHRH receptor positive 60 PLK1 SNALP 60 Previously Untreated 60 Receives Orphan Drug Designation 60 phase IIb study 60 Aliskiren 60 allogeneic stem cell 60 stage IIIB 60 Improves Outcomes 60 oral Janus kinase 60 Metastatic Renal Cell Carcinoma 60 Atypical Hemolytic Uremic Syndrome 60 CIMZIA ™ 60 Sangamo BioSciences Announces 60 CD# CEA 60 Akt inhibitor 60 stage IIIb 60 hGH CTP Phase 60 See CLINICAL PHARMACOLOGY 60 Ocrelizumab 60 Submits NDA 60 hypercholesterolemic patients 60 Relapsed Refractory Multiple Myeloma 60 oral ghrelin agonist 60 myelofibrosis polycythemia vera 60 Pirfenidone 60 plus gemcitabine 60 comparing XIENCE V 60 metastatic androgen independent 60 Phase III multicenter 60 humanised monoclonal antibody 60 Zemplar Capsules 60 Gemzar ® 60 investigational protease inhibitor 60 PROTECT AF 60 generation URAT1 inhibitor 60 Subgroup Analysis 60 SUCCEED trial 60 Amgen Vectibix 60 Cloretazine R 60 GVAX Pancreas Vaccine 60 nalbuphine ER 60 INS# [001] 60 Sym# 60 treatment naïve genotype 60 Chemophase 60 RNAi Therapeutic 60 Cardiovascular Outcomes 60 Ceflatonin R 60 VitiGam 60 Dacogen injection 60 SUPPRELIN R LA 60 R lenalidomide 60 Gastrointestinal Stromal Tumors 60 #I TM# 60 myelodysplastic myeloproliferative diseases 60 pivotal bioequivalence 60 Relapsing Remitting Multiple Sclerosis 60 Antiviral Activity 60 Aurora Kinase 60 IIa trial 60 Neoadjuvant Chemotherapy 60 Proxinium TM 60 Crofelemer budesonide foam 60 Vandetanib 60 ARIXTRA R 60 TroVax ® 60 Resistant Hypertension 60 double blinded placebo 60 Androxal TM 60 apricitabine ATC 60 Aeolus Pharmaceuticals Announces 60 severe oral mucositis 60 leading oral taxane 60 Voreloxin 60 PDX pralatrexate 60 uric acid lowering 60 relapsed multiple myeloma 60 Heterozygous Familial Hypercholesterolemia 60 Cannabinor 60 steroid refractory 60 Forodesine 60 Acute myelogenous leukemia 60 Phase #b/#a 60 CUSTOM III 60 toenail onychomycosis 60 dacetuzumab SGN 60 LymphoStat B TM 60 GATTEX ™ 60 Adjunctive Therapy 60 Chronic Hepatitis C 60 Randomised 60 Pegylated Interferon 60 ZYBRESTAT fosbretabulin 60 castration resistant hormone refractory 60 Pulmonary Arterial Hypertension 60 Testosterone MDTS ® 60 LibiGel ® 60 Clinical Trial Data 60 Novel Oral 60 Teva Provides Update 60 evaluating Prochymal 60 albiglutide 60 Syncria R 60 Phase IIb III 60 Paclitaxel Carboplatin 60 MAb therapy 60 Cloretazine R VNP#M 60 anti EGFR antibody 60 Glatiramer Acetate 60 Amrubicin 60 Phase III Pivotal Trial 60 RSD# oral 60 Tumor Response 60 Presents Preclinical Data 60 humanized interleukin 6 60 Ixempra 60 asymptomatic metastatic 60 approved incretin mimetic 60 CRMD# 60 IL# PE#QQR 60 docetaxel Taxotere ® 60 NO# [002] 60 thalidomide Thalomid 60 modified glutathione analog 60 Survival Benefit 60 PROVENGE sipuleucel T 60 Prostate Cancer Patients 60 PRECISE trial 60 Localized Prostate Cancer 60 OXi# 60 MIST II 60 lexidronam injection 60 Provectus Pharmaceuticals specializes 60 EVEREST II 60 Clinical Trial Results 60 PROVENGE ® 60 TMC# C# 60 oral methylnaltrexone 60 phase IIb 60 AA Amyloidosis 60 TOCOSOL Camptothecin 60 CINQUIL 60 OMNARIS HFA 60 Efficacy Trial 60 albiglutide currently 60 Phase III PREGNANT PROCHIEVE 60 TKM PLK1 60 Deforolimus 60 gefitinib Iressa 60 Long Term Efficacy 60 metastatic CRC 60 HBeAg negative 60 MEND CABG 60 Multiple Myeloma Patients 60 MCSP respectively 60 Cancer Vaccines 60 Temodar ® 60 Thiarabine 60 palifermin 60 Sphingomab TM 60 Advanced Ovarian Cancer 60 Lupus Nephritis 60 castration resistant prostate cancer 60 Thiovir 60 Delcath Phase III 60 novel therapeutic antibodies 60 Atiprimod 60 PEGylated interferon beta 1a 60 Phase 2a clinical trials 60 sorafenib Nexavar ® 60 sunitinib Sutent 60 CoFactor 60 LEP ETU 60 opioid naive 60 BOLDER II 60 Tesmilifene 60 Screening Trial DMIST 60 ThermoDox R 60 Carotid Stenting 60 FDA Accepts 60 Elagolix 60 Granted Orphan Drug 60 Myelofibrosis 60 TTF Therapy 60 granted Ortec 60 Phase 2a clinical 60 #D#C# 60 candidates Augment ™ 60 AZX# Phase 60 Adjuvant Therapy 60 Xcellerated T Cells 60 Pafuramidine 60 polycythemia vera essential thrombocythemia 60 Edge STudy 60 Genes Predict 60 BiTE R 60 NATRECOR R 60 Vicinium TM 60 Trofex TM 60 Phase IIb trials 60 lintuzumab 60 ICON7 60 Myocet 60 Ophena TM 60 Neulasta ® 60 developed preclinically 60 PNT# 60 Antitumor activity 60 Dasatinib 60 REG2 60 ovarian endometrial 60 Bavituximab 60 Paraplatin ® 60 Lymphocytic 60 MERLIN TIMI 60 Diamyd ® 60 Randomized Clinical Trial 60 PKC# 60 Pfizer Sutent 60 ER CHOP 60 Ovarian Cancer Patients 60 Systemic Sclerosis 60 evaluating bafetinib 60 Slow Progression 60 Vitro Activity 60 3 registrational trial 60 CCX# B 60 GRN# 60 targeting miR 60 allogeneic HSCT 60 Medullary Thyroid Cancer 60 BCG refractory carcinoma 60 Belimumab 60 RhuDex TM 60 semi synthetic lipoglycopeptide 60 COSIRA trial 59 coinfected patients 59 refractory colorectal cancer 59 HDAC Inhibitor 59 AKT inhibitor 59 Vitrasert R 59 alfa 2a 59 EGS# 59 formerly LymphoStat B 59 MKC# MKC# PP 59 recurrent glioblastoma 59 CMV vaccine 59 Perifosine KRX 59 E1 INT TM 59 humanized therapeutic 59 Xelox 59 Curaxin CBLC# 59 adjuvant GIST 59 non nucleoside HCV 59 Cimzia TM 59 ixabepilone 59 metastatic ocular 59 sarcoma melanoma 59 metastatic CRPC 59 medically inoperable 59 candidate deforolimus 59 rindopepimut 59 GALNS 59 VICTOR E3 59 Randomized Clinical Trials 59 Bucindolol 59 Adjuvant chemotherapy 59 Varespladib 59 drug conjugate 59 AVN# Phase 59 LBH# 59 Shows Statistically Significant 59 refractory multiple myeloma 59 oral deforolimus 59 Combination Treatment 59 Decompensated Heart Failure 59 Sudhir Agrawal D.Phil 59 azilsartan medoxomil 59 Preclinical Data 59 castrate resistant prostate cancer 59 NSABP B 59 R sorafenib tablets 59 tubulin inhibitor 59 Phase III ThermoDox 59 ADXS# 59 Tamibarotene 59 Inhaled nitric oxide 59 dose escalation Phase 59 Myelodysplastic Syndrome MDS 59 Traficet EN 59 GW# [003] 59 BRAF mutant 59 Chronic Lymphocytic Leukemia CLL 59 BiovaxID TM 59 Anticancer Compound 59 Fludara ® 59 ADVANCE PD 59 TORISEL 59 Epidermal Growth Factor Receptor 59 vemurafenib 59 generation PNP inhibitor 59 RE LY 59 lymphoid malignancies 59 Anticancer Drug 59 hepatitis C HCV 59 phase Ib clinical 59 visilizumab 59 orBec 59 catheter occlusion 59 biliary tract cancer 59 Mycophenolate Mofetil 59 class mGluR5 inhibitor 59 Nymox NX 59 huN# DM1 59 ACCLAIM COPD 59 Tectin TM 59 EXPLORE Xa 59 HIV HCV coinfected 59 axitinib 59 Val HeFT 59 Fibrin Pad 59 pomalidomide 59 Is Well Tolerated 59 imatinib Gleevec 59 Phase 2a trial 59 Vitaxin 59 drug NP2 Enkephalin 59 oral dual endothelin 59 ADVANCE ILLUMINATE 59 Shows Efficacy 59 antibody MT# 59 NPC 1C 59 Bevacizumab 59 EGFr expressing metastatic colorectal 59 plus dacarbazine 59 CAPRIE 59 candidates Azedra TM 59 generation Hsp# inhibitor 59 monoclonal antibody conjugated 59 zileuton IV 59 OncoVex 59 TRIOLEX HE# APOPTONE HE# 59 neovascular diseases 59 recurrent glioblastoma multiforme GBM 59 ragweed allergic children 59 hA# 59 Tyrima 59 IV metastatic melanoma 59 Diabetic Macular Edema 59 Metabolic Efficiency 59 Doxil ® 59 evaluating ASA# 59 Allovectin 7 ® 59 MVax R 59 Deferiprone 59 Onrigin 59 hormone refractory 59 Zalypsis 59 Phase #/#a trial 59 investigational pan BCR 59 CYP#A# isoenzyme 59 Nilotinib 59 Anti Tumor 59 Panzem 59 multicenter Phase III 59 ORENCIA ® 59 Phase #/#a 59 prucalopride 59 Phase III HEAT 59 resectable pancreatic cancer 59 Sprycel dasatinib 59 relapsed myeloma 59 tumor lysis syndrome 59 NU# direct 59 Azedra 59 Oral Insulin Capsule 59 anthracycline taxane 59 Lung Cancer Patients 59 Targretin capsules 59 Advanced Colorectal Cancer 59 Laquinimod 59 ENDEAVOR III 59 ENGAGE AF TIMI 59 docetaxel Taxotere R 59 data management Clintrial 59 endocrine responsive 59 dose intramuscular 59 gp# vaccine 59 Bafetinib 59 paclitaxel cisplatin 59 multicenter multinational 59 Thromboembolic 59 hyperplasia BPH 59 EURIDIS 59 Ceplene/IL-2 59 StaphVAX R 59 Radical Prostatectomy 59 complement inhibitor eculizumab